Open main menu

Deferiprone (tradenames include Ferriprox) is a drug that chelates iron and is used to treat iron overload in thalassaemia major.[1] It was first approved for use in treating thalassaemia major in 1994[2] and had been licensed for use in Europe and Asia for many years while awaiting approval in Canada and the United States.[1] On October 14, 2011, it was approved for use in the US under the FDA's accelerated approval program.[3]

Clinical data
Trade namesFerriprox
AHFS/Drugs.comInternational Drug Names
License data
  • US: D (Evidence of risk)
Routes of
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life2 to 3 hours
ExcretionRenal (75 to 90% in 24 hours)
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.157.470 Edit this at Wikidata
Chemical and physical data
Molar mass139.152 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)


Deferiprone was at the center of a protracted struggle between Nancy Olivieri, a Canadian haematologist and researcher, and the Hospital for Sick Children and the pharmaceutical company Apotex, that started in 1996 and delayed approval of the drug in North America.[4] Olivieri's data suggested deferiprone leads to progressive hepatic fibrosis.[5][6][7]

See alsoEdit


  1. ^ a b Savulescu, J (2004). "Thalassaemia major: The murky story of deferiprone". BMJ. 328 (7436): 358–9. doi:10.1136/bmj.328.7436.358. PMC 341373. PMID 14962851.
  2. ^ Staff, Cipla. Cipla's History
  3. ^ FDA NEWS RELEASE: FDA Approves Ferripox (deferiprone) to Treat Patients with Excess Iron in the Body, Oct. 14, 2011
  4. ^ Viens, A M; Savulescu, J (2004). "Introduction to the Olivieri symposium". Journal of Medical Ethics. 30 (1): 1–7. doi:10.1136/jme.2003.006577. PMC 1757126. PMID 14872065.
  5. ^ Brittenham, G. M; Nathan, D. G; Olivieri, N. F; Porter, J. B; Pippard, M; Vichinsky, E. P; Weatherall, D. J (2003). "Deferiprone and hepatic fibrosis". Blood. 101 (12): 5089–90, author reply 5090–1. doi:10.1182/blood-2002-10-3173. PMID 12788794.
  6. ^ Wanless, I. R; Sweeney, G; Dhillon, A. P; Guido, M; Piga, A; Galanello, R; Gamberini, M. R; Schwartz, E; Cohen, A. R (2002). "Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia". Blood. 100 (5): 1566–9. doi:10.1182/blood-2002-01-0306. PMID 12176871.
  7. ^ Cribb, Robert (2019-02-27). "UHN patients given unlicensed drug that led to diabetes, liver dysfunction and one death, study finds". The Star. Toronto. Retrieved 2019-02-27.